Identification and characterisation of the dose response of otelixizumab in new onset type 1 diabetes patients

Antonio Napolitano(Bambino Gesù Children's Hospital), Bart Keymeulen(Vrije Universiteit Brussel), André van Maurik(PsiOxus Therapeutics (United Kingdom)), Chantal Mathieu(KU Leuven), Pieter Gillard(Research Foundation - Flanders), Robert Hilbrands, Frans Gorus(Vrije Universiteit Brussel), Ursule Van de Velde(Center for Beta Cell Therapy in Diabetes), Nicolas Wisniacki, Derek Inman(Kavli Institute for the Physics and Mathematics of the Universe)
VUBIR (Vrije Universiteit Brussel)
September 1, 2019
Cited by 0

Related Papers

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease
|Annals of Internal Medicine|2012|362
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
|Diabetologia|2010|313
Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes
|Nature Medicine|2016|301